Innovative Therapies in Europe

DIA-EUCOPE Workshop: 5 Years of ATMPs on the Market - Lessons Learned

Session 2: Is Zynteglo representative for the ATMPs failure in Europe? Are EU systems broken for innovative therapies?

Session Chair(s)

Alexander Natz, JD

• Secretary General
• European Confederation of Pharmaceutical Entrepreneurs, Belgium

Topics covered in this session include:

• Case study & domino effect
• The regulatory aspects
• Historical background for withdrawals